Ann Clin Microbiol.  2024 Sep;27(3):179-183. 10.5145/ACM.2024.27.3.5.

Essential data for developing bacteriophage therapeutics

• Yong D

• KMID: 2559807
• DOI: http://doi.org/10.5145/ACM.2024.27.3.5

Reference

1. O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. 2016. https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf [Online] (last visited on 28 August 2024).

2. Jędrusiak A, Fortuna W, Majewska J, Górski A, Jończyk-Matysiak E. Phage interactions with the nervous system in health and disease. Cells 2023;12:1720.

3. Dedrick RM, Guerrero-Bustamante CA, Garlena RA, Russell DA, Ford K, Harris K, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med 2019;25:730-3.

4. Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother 2017;61:10-1128.

5. Suh GA, Lodise TP, Tamma PD, Knisely JM, Alexander J, Aslam S, et al. Considerations for the use of phage therapy in clinical practice. Antimicrob Agents Chemother 2022;66:e0207121.

6. Łusiak-Szelachowska M, Międzybrodzki R, Drulis-Kawa Z. Cater K, Knežević P, Winogradow C, et al. Bacteriophages and antibiotic interactions in clinical practice: what we have learned so far. J Biomed Sci 2022;29:23.

7. Chae D. Phage-host-immune system dynamics in bacteriophage therapy: basic principles and mathematical models. Transl Clin Pharmacol 2023;31:167-90.

8. Aslam S, Lampley E, Wooten D, Karris M, Benson C, Strathdee S, et al. Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrugresistant bacterial infections at a single center in the United States. Open Forum Infect Dis 2020;27:ofaa389.

9. Jault P, Leclerc T, Jennes S, Pirnay JP, Que YA, Resch G, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis 2019;19:35-45.

10. Suh GA, Ferry T, Abdel MP. Phage therapy as a novel therapeutic for the treatment of bone and joint infections. Clin Infect Dis 2023;77(Suppl 5):S407-15.

11. Furfaro LL, Payne MS, Chang BJ. Bacteriophage therapy: clinical trials and regulatory hurdles. Front Cell Infect Microbiol 2018;8:376.

12. Pires DP, Costa AR, Pinto G, Meneses L, Azredo J. Current challenges and future opportunities of phage therapy. FEMS Microbiol Rev 2020;44:684-700.

13. Fabijan AP, Iredell J, Danis-Wlodarczyk K, Kebriaei R, Abedon ST. Translating phage therapy into the clinic: recent accomplishments but continuing challenges. PLoS Biol 2023;21:e3002119.

14. Karn SL, Gangwar M, Kumar R, Bhartiya SK, Nath G. Phage therapy: a revolutionary shift in the management of bacterial infections, pioneering new horizons in clinical practice, and reimagining the arsenal against microbial pathogens. Front Med 2023;10:1209782.